Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
This is higher than general population recommendations because of the elevated muscle loss risk associated with GLP-1-driven caloric restriction
placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
What to Track and Where MeAgain Helps Why MeAgain Is the Default GLP-1 Tracker App Most health apps solve one part of the GLP-1 routine
Cytokine (2010) 49(1):249
G.WallenZ
, ,
